Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 39 |
| Active Pipeline (Recruiting Now) | 33 (20) |
| Completed vs Stopped Early | 1 / 5 (12.8%) |
| Median Closed Actual Enrollment | 25 participants |
| Physical Hospital Site Disclosure | 100.0% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| St. Jude Children's Research Hospital | Memphis, TN | 38 |
| Stanford Health Care and Stanford Cancer Institute | Stanford, CA | 4 |
| Dana-Farber Cancer Institute | Boston, MA | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT05535166 | Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase II | RECRUITING |
| NCT05955261 | A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia | Phase II | RECRUITING |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for St. Jude Children's Research Hospital across sibling Meru public-data platforms.
Explore interactive annual charts and M&A subsidiary rollups in the St. Jude Children's Research Hospital Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.